X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

MORRIS PLAINS, NJ-Johnson & Johnson’s much-heralded $16.6-billion acquisition of rival Pfizer’s over-the-counter product line will apparently take another twist, with the two companies occupying opposite ends of Pfizer’s sprawling campus here. According to a published report, the New Brunswick-based J&J will take over two under-construction buildings totaling nearly 700,000 sf on the eastern end of Pfizer’s campus. Spokesmen for both companies confirmed the general plan but declined further comment.

The New York City-based Pfizer, meanwhile, will continue to use the western end of the 175-acre campus, according to reports, where it has its technical center and other operations. The two buildings that J&J will apparently take over to house its now-expanded OTC product line were being built for Pfizer’s use, but that process went into a slow-down mode last year after the pharma giant announced some cost-cutting initiatives.

While a spokesman for J&J did confirm the pending arrangement, a statement issued on behalf of company chairman William Weldon indicated that final facility decisions wouldn’t be formally announced until after top management of the companies’ two consumer products operations worked out the details in the weeks ahead. A spokesman would not comment on details of the pending transaction, including possible sale of a portion of the Pfizer site to J&J. The acquisition adds such well-known brand names as Listerine, Visine, Sudafed, Zantac, Benadryl and Rolaids, among others, to J&J’s product line.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?

 

GlobeSt

Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt
Live Chat

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.